SHINE Medical Technologies LLC recently announced that it has entered a multi-year contract with the University of Missouri Research Reactor, for irradiation of ytterbium-176, the starting material for the production of ‘no carrier added’ grade lutetium-177 (Lu-177), a therapeutic isotope that has shown great promise for improving patient outcomes for a range of cancers.

Lu-177 is a low-energy beta-particle emitter that works by directly irradiating cancer cells after being delivered to the cancer site by a targeting molecule. Energy from Lu-177 only travels a short distance once it reaches cancer cells, enabling the isotope to destroy those cells with little damage to surrounding tissue. Lu-177-based therapy has been approved by the U.S. Food and Drug Administration for the treatment of neuroendocrine cancers. It also shows promise for the treatment of other cancers, including metastatic prostate, breast, liver, and brain cancers.

To read more please visit:

https://shinemed.com/shine-medical-announces-agreement-with-murr/

Source: Shine Medical